DoW Autism Clinical Trial Award | HT942526ARPCTA

FY26 DoW Autism Research Program (ARP) Clinical Trial Award (HT942526ARPCTA) - FAQs

1) What is the FY26 DoW Autism Research Program (ARP) Clinical Trial Award?

The FY26 ARP Clinical Trial Award is a discretionary grant opportunity administered through the Defense Health Agency Contracting Activity (DHACA). It is intended to support the fast launch and execution of autism-focused clinical trials that could meaningfully improve treatment or day-to-day management of autism, with an emphasis on actionable results and real-world impact rather than purely exploratory work.

2) What is the main purpose of this award?

The award is designed to move credible clinical ideas forward quickly by funding clinical trials that can generate practical, usable findings that improve care or management of autism in real-world settings.

3) What kinds of studies are supported under this opportunity?

This opportunity is specifically geared toward clinical trials across a wide range of intervention types. Proposed projects may evaluate new or emerging products, pharmacologic agents (including drugs or biologics), medical devices, clinical guidance, and other novel approaches or technologies intended to improve care.

4) Are early-stage clinical trials allowed, or does this require a large, late-stage trial?

The opportunity is broad in terms of trial stage and size. It allows proposals ranging from smaller, early proof-of-concept efforts (such as pilot studies, first-in-human work, or phase 0-style feasibility trials) to larger trials designed to determine efficacy in appropriate patient populations.

5) Can an application focus on feasibility rather than efficacy?

Yes. Applicants can propose an early trial intended to validate feasibility and refine the design of later-stage studies, or a more advanced trial aimed at answering efficacy questions more definitively.

6) What does the program mean by "fast launch and execution"?

The award is positioned for teams that are ready to run a clinical trial relatively quickly. The description emphasizes rapid movement of credible clinical ideas into execution, prioritizing studies that can produce actionable results and real-world impact.

7) What are the "Areas of Interest" and do applicants need to address them?

A key expectation is alignment with the FY26 ARP Clinical Trial Award Areas of Interest. While the specific Areas of Interest are not listed in the provided information, applications are strongly encouraged to directly address one of these priority topics, which typically influences competitiveness during review.

8) How should applicants show alignment with an Area of Interest?

Applicants should be prepared to clearly map the trial question, endpoints, and target population to the most appropriate stated priority area. The solicitation signals that this alignment is an important factor in competitiveness.

9) Is there a partnering option for early-career investigators?

Yes. The funding mechanism includes an optional partnering structure intended to bring early-career investigators into autism clinical trial leadership. Under this option, an experienced principal investigator serves as the Initiating PI and an Early-Career Investigator serves as a Partnering PI.

10) What benefit is offered for using the partnering PI structure?

The program offers a higher level of funding when an application includes the Initiating PI and an Early-Career Investigator Partnering PI. This structure is meant to support mentorship and career development while maintaining appropriate oversight and operational experience for successful trial execution.

11) Is the partnering PI structure required?

No. The partnering structure is described as optional. However, it is a distinctive feature of the mechanism and may be used by teams seeking to integrate early-career leadership development into the trial.

12) What does the opportunity require regarding community collaboration?

Community collaboration is described as a non-negotiable element and essential for maximizing translational value and real-world relevance. Research teams must build and use effective, equitable partnerships with community members throughout planning and implementation, rather than treating engagement as a one-time advisory step.

13) Who can serve as a community partner for this award?

Each application is expected to identify at least one community partner. Examples include an Autistic individual, a caregiver, or representatives from community-based organizations who will provide ongoing advice and consultation throughout the life of the project.

14) What level of community engagement is expected?

The notice indicates that community engagement should be meaningfully integrated into the clinical trial workflow and sustained over the project period. It should not be limited to passive participation such as attending seminars or occasional meetings.

15) What documentation is required for community collaboration?

Applicants are directed to document their approach through a Community Collaboration Plan, referenced as Attachment 12 in the full funding package. Reviewers are expected to look for concrete structures, roles, and communication plans that demonstrate active and sustained partnership.

16) What is the Funding Opportunity Number for this grant?

The Funding Opportunity Number is HT942526ARPCTA.

17) What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 12.420.

18) How is this opportunity categorized?

It is categorized under science and technology and other research and development.

19) Who is eligible to apply?

The eligible applicant pool is listed as unrestricted, indicating broad eligibility unless additional constraints are included in the full announcement.

20) When was this opportunity created and what is the closing date?

The opportunity was created on 2026-05-21. The original closing date is 2026-10-22.

21) How many awards are expected to be made?

The expected number of awards is listed as 1.

22) Is there a maximum award amount (ceiling)?

The award ceiling is not specified in the provided information. Applicants are expected to consult the full solicitation for budget limits, allowable costs, and whether different caps apply depending on the scope of the trial or use of the partnering PI option.

23) What types of impacts is the program looking for?

The program emphasizes clinical trials that could meaningfully improve treatment or day-to-day management of autism and that can yield actionable results with real-world relevance, rather than work that is purely exploratory.

24) What overall characteristics make an application a good fit for this award?

Based on the provided description, strong-fit applications are those that are ready to execute a clinical trial quickly, align clearly with the FY26 ARP Clinical Trial Award Areas of Interest, integrate authentic community partnership from planning through implementation, and, when applicable, build early-career leadership capacity through the Initiating PI/Partnering PI structure.